Jon M Richards

US Patent:

7993638, Aug 9, 2011

Filed:

Feb 23, 2007

Appl. No.:

12/281197

Inventors:

Zeling Cai - San Diego CA, US
Ann Moriarty - Poway CA, US
Per A. Peterson - Rancho Santa Fe CA, US
Jon M. Richards - Glenview IL, US

Assignee:

Janssen Pharmaceutica NV

International Classification:

A61K 38/19
A61K 38/20
A61K 38/21
A61K 35/12

US Classification:

424 852, 424 857, 424 9371

Abstract:

In a cancer treatment combining cell therapy with chemotherapy, autologous CD8 T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-α-2b stimulatory cytokines.

US Patent:

20090004142, Jan 1, 2009

Filed:

Jul 24, 2007

Appl. No.:

11/782264

Inventors:

Didier J. Leturcq - San Diego CA, US
Ann M. Moriarty - Poway CA, US
Michael R. Jackson - Del Mar CA, US
Per A. Peterson - Basking Ridge NJ, US
Jon M. Richards - Glenview IL, US

International Classification:

A61K 38/21
A61K 35/12
A61P 35/00

US Classification:

424 857, 424 9321

Abstract:

T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; ) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8 T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.